Form 4: Aquestive Therapeutics' Chief Medical Officer, Carl N. Kraus, Reports Transactions in Company Stock
SEC Form 4 Filing
Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options.
Summary
- On March 7, 2025, Carl N. Kraus, Chief Medical Officer of Aquestive Therapeutics, acquired 70,000 shares of common stock represented by restricted stock that vests in three annual installments.
- Kraus also disposed of 8,115 shares of common stock to satisfy tax withholding obligations related to the vesting of previously granted Restricted Stock Units (RSUs) at a price of $2.65 per share.
- Additionally, Kraus acquired 30,000 non-qualified stock options with an exercise price of $2.65, vesting in three annual installments and expiring on March 7, 2035.
- Following these transactions, Kraus beneficially owns 313,566 shares of common stock and 30,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. There are no indications of significant positive or negative developments.
Positives
- The acquisition of 70,000 restricted shares by the Chief Medical Officer could be interpreted as a sign of confidence in the company's future prospects.
- The granting of 30,000 stock options aligns the executive's interests with those of the shareholders.
Negatives
- The disposal of 8,115 shares to cover tax obligations, while routine, represents a slight decrease in the executive's holdings.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in company stock. It is common for executives to receive stock options and restricted stock as part of their compensation packages, aligning their interests with those of shareholders.
Stakeholder Impact
- The transactions have a minor impact on shareholders, providing transparency into executive stock ownership.
- Employees may view the stock grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/07/2025 | Date of transactions: acquisition of restricted stock and stock options, disposal of shares for tax obligations. |
| 03/07/2035 | Expiration date of the non-qualified stock options. |
| 03/11/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.